News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
491,860 Results
Type
Article (8613)
Company Profile (142)
Press Release (483105)
Multimedia
Podcasts (5)
Webinars (6)
Section
Business (167585)
Career Advice (309)
Deals (25847)
Drug Delivery (11)
Drug Development (54612)
Employer Resources (14)
FDA (9889)
Job Trends (8668)
News (240616)
Policy (18113)
Tag
2027 BioMidwest Digital (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Digital (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (521)
Accelerated approval (28)
ADA (18)
Adcomms (3)
Allergies (101)
Alliances (33476)
ALS (118)
Alzheimer's disease (1018)
Antibody-drug conjugate (ADC) (330)
Approvals (10587)
Artificial intelligence (358)
ASCO (162)
Autoimmune disease (239)
Automation (32)
Bankruptcy (263)
Belgium (4)
Best Places to Work (7047)
BIO (36)
Biologics (29)
BIOSECURE Act (1)
Biosimilars (150)
BioSpace Insights (20)
Biotechnology (89)
Bispecific (11)
Bladder cancer (142)
Brain cancer (35)
Breast cancer (532)
Cancer (4008)
Cardiovascular disease (238)
Career advice (252)
Career pathing (1)
CAR-T (191)
CDC (2)
CDMO (37)
Celiac Disease (3)
Cell therapy (516)
Cervical cancer (36)
Clinical research (49735)
Collaboration (1368)
Commercialization (20)
Compensation (1606)
Complete response letters (37)
COVID-19 (956)
CRISPR (66)
CRO (1)
C-suite (843)
Cystic fibrosis (91)
Data (6343)
Denatured (4)
Depression (108)
Dermatology (94)
Diabetes (380)
Diagnostics (4271)
Digital health (40)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (172)
Drug pricing (7)
Drug shortages (5)
Duchenne muscular dystrophy (178)
Earnings (74071)
Editorial (3)
Employer branding (2)
Employer resources (14)
Events (89097)
Executive appointments (734)
Eye disease (3)
FDA (12806)
Fibrodysplasia Ossificans Progressiva (11)
Fragile X (1)
Friedreich's ataxia (20)
Frontotemporal dementia (25)
Funding (1015)
Gene editing (132)
Generative AI (14)
Gene therapy (363)
GLP-1 (323)
Government (996)
Grass and pollen (2)
Guidances (286)
Healthcare (9551)
Hematology (99)
HIV (57)
Huntington's disease (25)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (76)
Immunology and inflammation (117)
Immuno-oncology (70)
Indications (177)
Infectious disease (1185)
Inflammatory bowel disease (141)
Inflation Reduction Act (4)
Influenza (105)
Intellectual property (272)
Interviews (43)
IPO (12445)
IRA (2)
Job creations (1979)
Job search strategy (242)
JPM (2)
Kidney cancer (17)
Kidney disease (64)
Labor market (1)
Layoffs (65)
Legal (5209)
Licensing (41)
Liver cancer (47)
Longevity (23)
Lung cancer (572)
Lung diease (8)
Lymphoma (281)
Machine learning (29)
Management (3)
Manufacturing (620)
Marketing (15)
MASH (120)
Medical affairs (2)
Medical device (8715)
Medtech (8889)
Mergers & acquisitions (14504)
Metabolic disorders (771)
mRNA (97)
Multiple sclerosis (111)
Multispecific (3)
NASH (4)
Netherlands (1)
Neurodegenerative disease (240)
Neuropsychiatric disorders (40)
Neuroscience (1952)
Neurotech (1)
NextGen: Class of 2026 (3184)
Non-profit (859)
Now hiring (2)
Obesity (243)
Opinion (15)
Ovarian cancer (184)
Pain (184)
Pancreatic cancer (224)
Parkinson's disease (224)
Partnered (13)
Patents (528)
Patient advocacy (2)
Patient recruitment (559)
Patient selection (36)
Peanut (33)
People (41655)
Peptides (12)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (16303)
Phase 2 (22181)
Phase 3 (14970)
Pipeline (8347)
Policy (22)
Postmarket research (1605)
Preclinical (6751)
Press Release (34)
Prostate cancer (202)
Psychedelics (11)
Radiopharmaceuticals (204)
Rare diseases (634)
Real estate (3048)
Recruiting (6)
Regenerative medicine (11)
Regulatory (15369)
Reports (23)
Research institute (615)
Resumes & cover letters (45)
Rett syndrome (45)
RNA editing (9)
RSV (56)
Schizophrenia (108)
Series A (175)
Series B (129)
Service/supplier (5)
Sickle cell disease (64)
Special edition (1)
Spinal muscular atrophy (92)
Sponsored (7)
Startups (2049)
Stem cells (1)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (56)
Tariffs (1)
The Weekly (1)
Vaccines (535)
Venture capital (17)
Weight loss (82)
Wet AMD (1)
Women's health (96)
Date
Today (22)
Last 7 days (354)
Last 30 days (1450)
Last 365 days (19388)
2026 (15231)
2025 (19523)
2024 (23324)
2023 (26921)
2022 (34999)
2021 (37624)
2020 (33864)
2019 (23529)
2018 (17670)
2017 (19044)
2016 (18109)
2015 (24445)
2014 (21807)
2013 (18214)
2012 (20322)
2011 (20544)
2010 (20414)
Location
Africa (243)
Alabama (80)
Alaska (2)
Arizona (318)
Arkansas (12)
Asia (18653)
Australia (2170)
California (12774)
Canada (3341)
China (622)
Colorado (524)
Connecticut (444)
Delaware (228)
Europe (26615)
Florida (1927)
Georgia (405)
Hawaii (3)
Idaho (46)
Illinois (774)
India (64)
Indiana (331)
Iowa (17)
Japan (447)
Kansas (105)
Kentucky (33)
Louisiana (27)
Maine (27)
Maryland (1268)
Massachusetts (8415)
Michigan (321)
Minnesota (588)
Mississippi (4)
Missouri (83)
Montana (21)
Nebraska (11)
Nevada (130)
New Hampshire (60)
New Jersey (2836)
New Mexico (12)
New York (2997)
North Carolina (1351)
North Dakota (5)
Northern California (6454)
Ohio (308)
Oklahoma (14)
Oregon (16)
Pennsylvania (2386)
Puerto Rico (24)
Rhode Island (30)
South America (410)
South Carolina (80)
South Dakota (1)
Southern California (5321)
Tennessee (128)
Texas (2113)
United States (41535)
Utah (386)
Vermont (1)
Virginia (163)
Washington D.C. (40)
Washington State (991)
West Virginia (1)
Wisconsin (81)
Wyoming (1)
491,860 Results for "immunogen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
September 23, 2026
·
7 min read
Rare diseases
BioMarin Axes Pre-Clinical PKU Drug, Citing Underwhelming Immunogenicity
BMN 390 fell short of an immunogenicity threshold that BioMarin was looking for to support its further development. Employees working on the program have been redeployed within the company.
August 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Apollo Therapeutics Announces Positive Immunogenicity Data and Cross-Species Activity from Phase 1 Trial of APL-10456, a Pan-Rhinovirus Vaccine for the Prevention of COPD Exacerbations
August 25, 2026
·
6 min read
Press Releases
ProImmune Introduces Mastering Immunity 2026 - Shanghai Symposium to Address Key Immunogenicity Challenges
January 21, 2026
·
2 min read
Press Releases
EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide
December 9, 2025
·
2 min read
Genetown
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2024
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of January 31, 2024, the grant of restricted stock units covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to eleven new employees.
February 1, 2024
·
1 min read
Deals
AbbVie Completes Acquisition of ImmunoGen
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ImmunoGen (NASDAQ: IMGN).
February 12, 2024
·
8 min read
Genetown
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2024
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of December 29, 2023, the grant of restricted stock units covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc.
January 3, 2024
·
1 min read
Genetown
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2023
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of November 30, 2023, the grant of restricted stock units covering 112,252 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to twelve new employees.
December 1, 2023
·
1 min read
Genetown
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE ® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer.
December 5, 2023
·
6 min read
1 of 49,186
Next